Chemours Past Earnings Performance
Past criteria checks 0/6
Chemours's earnings have been declining at an average annual rate of -13.4%, while the Chemicals industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 2.8% per year.
Key information
-13.4%
Earnings growth rate
-11.7%
EPS growth rate
| Chemicals Industry Growth | 12.9% |
| Revenue growth rate | 2.8% |
| Return on equity | -32.1% |
| Net Margin | -3.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Drama At The Chemours Company Opens The Door For Upside
Mar 29The Chemours Company (NYSE:CC) Not Doing Enough For Some Investors As Its Shares Slump 37%
Mar 01
Chemours: The Case Amidst Board Trouble, I Say Buy The Weakness
Feb 29Chemours (NYSE:CC) Has Announced A Dividend Of $0.25
Feb 17Chemours: Technological Innovation Presents Excellent Opportunities For Growth
Dec 23Chemours (NYSE:CC) Will Pay A Dividend Of $0.25
Oct 30The Chemours Company (NYSE:CC) Shares Could Be 21% Above Their Intrinsic Value Estimate
Oct 28Chemours: Volatile Bottom Line Needs Consistency
Oct 06The Chemours Company: Portfolio Optimization Resulting In Compounding Growth
Sep 19Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt
Jul 18Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?
Jul 03The Chemours Company: On A Nice Run
Jul 03Is The Chemours Company (NYSE:CC) Potentially Undervalued?
May 15Is Chemours (NYSE:CC) Using Too Much Debt?
Apr 06The Chemours Company: Market Volatility May Present Buying Opportunity
Feb 13Chemours (NYSE:CC) Is Paying Out A Dividend Of $0.25
Feb 11At US$34.94, Is It Time To Put The Chemours Company (NYSE:CC) On Your Watch List?
Feb 09Revenue & Expenses BreakdownBeta
How Chemours makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6,027 | -238 | 526 | 108 |
| 30 Sep 23 | 6,004 | -309 | 567 | 112 |
| 30 Jun 23 | 6,294 | -87 | 572 | 117 |
| 31 Mar 23 | 6,566 | 489 | 689 | 114 |
| 31 Dec 22 | 6,794 | 578 | 705 | 118 |
| 30 Sep 22 | 7,031 | 908 | 688 | 117 |
| 30 Jun 22 | 6,933 | 881 | 670 | 111 |
| 31 Mar 22 | 6,673 | 746 | 560 | 113 |
| 31 Dec 21 | 6,345 | 608 | 583 | 107 |
| 30 Sep 21 | 6,108 | 394 | 582 | 104 |
| 30 Jun 21 | 5,662 | 256 | 572 | 100 |
| 31 Mar 21 | 5,100 | 215 | 539 | 93 |
| 31 Dec 20 | 4,969 | 219 | 526 | 93 |
| 30 Sep 20 | 4,984 | -117 | 463 | 86 |
| 30 Jun 20 | 5,140 | -117 | 472 | 83 |
| 31 Mar 20 | 5,455 | -46 | 508 | 82 |
| 31 Dec 19 | 5,526 | -52 | 536 | 80 |
| 30 Sep 19 | 5,637 | 407 | 600 | 82 |
| 30 Jun 19 | 5,876 | 606 | 610 | 83 |
| 31 Mar 19 | 6,284 | 792 | 647 | 84 |
| 31 Dec 18 | 6,638 | 995 | 630 | 82 |
| 30 Sep 18 | 6,749 | 1,081 | 603 | 80 |
| 30 Jun 18 | 6,705 | 1,013 | 597 | 80 |
| 31 Mar 18 | 6,476 | 893 | 578 | 82 |
| 31 Dec 17 | 6,183 | 746 | 592 | 81 |
| 30 Sep 17 | 5,930 | 288 | 582 | 82 |
| 30 Jun 17 | 5,744 | 285 | 605 | 81 |
| 31 Mar 17 | 5,540 | 106 | 616 | 76 |
| 31 Dec 16 | 5,400 | 7 | 591 | 81 |
| 30 Sep 16 | 5,438 | 151 | 605 | 89 |
| 30 Jun 16 | 5,526 | -82 | 615 | 87 |
| 31 Mar 16 | 5,651 | -82 | 598 | 97 |
| 31 Dec 15 | 5,717 | -90 | 632 | 97 |
| 30 Sep 15 | 5,906 | 75 | 634 | 101 |
| 30 Jun 15 | 6,052 | 211 | 653 | 116 |
| 31 Mar 15 | 6,226 | 345 | 679 | 129 |
| 31 Dec 14 | 6,432 | 400 | 685 | 143 |
| 30 Sep 14 | 6,539 | 431 | 715 | 151 |
| 31 Dec 13 | 6,859 | 423 | 768 | 164 |
Quality Earnings: CC is currently unprofitable.
Growing Profit Margin: CC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CC is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare CC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CC is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-11.9%).
Return on Equity
High ROE: CC has a negative Return on Equity (-32.07%), as it is currently unprofitable.